Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.
Departamento de Ciências e Tecnologias, Universidade Estadual do Sudoeste da Bahia, Jequié, Brazil.
J Neural Transm (Vienna). 2019 Oct;126(10):1291-1301. doi: 10.1007/s00702-019-02041-9. Epub 2019 Jul 11.
Parkinson's disease (PD) is classically considered a motor disease; however, several non-motor symptoms are also present, including psychiatric complaints. In recent decades, the metals Ca, Fe, and Zn have gained prominence as potential etiologic factors in motoric signs of PD. However, metal alterations could be associated with the non-motor symptoms of PD. We wished to correlate the levels of these metals with the co-occurrence of depression, anxiety, and psychotic symptoms in PD patients. To this end, the Beck Depression Inventory, the Beck Anxiety Inventory, and the Scales for Outcomes in Parkinson's disease-Psychiatric Complications (SCOPA-PC) were implemented to evaluate mood disorders and psychiatric complications. Flame atomic absorption spectrometry (FAAS) was used to assess concentrations of Ca, Fe, and Zn in hair samples collected from 22 clinically diagnosed PD patients, which represented the entire cohort of accessible patients in a Brazilian health registry, and 33 healthy individuals. While Ca and Fe alterations were not found to be associated with psychiatric complaints in the PD group, significantly higher levels of Zn were correlated in PD patients with depression and some psychotic symptoms. Within individual domains of the SCOPA-PC, significantly higher levels of Zn were correlated with the presence of hallucination, illusion, and paranoid ideation when compared to controls and PD patients who did not present these symptoms. Although our sample size is small and findings need to be replicated in larger and heterogeneous populations, our results provide a new perspective on the use of monitoring of Zn levels as a potential biomarker of psychiatric complaints, and may be useful in the development of more effective therapeutic approaches for the management of PD patients with co-occurrence of psychiatric disorders.
帕金森病(PD)通常被认为是一种运动疾病;然而,也存在几种非运动症状,包括精神科投诉。近几十年来,钙、铁和锌等金属已成为 PD 运动症状潜在病因因素的焦点。然而,金属改变可能与 PD 的非运动症状有关。我们希望将这些金属的水平与 PD 患者抑郁、焦虑和精神病症状的同时发生相关联。为此,实施了贝克抑郁量表、贝克焦虑量表和帕金森病结局量表-精神并发症(SCOPA-PC),以评估情绪障碍和精神并发症。火焰原子吸收光谱法(FAAS)用于评估从 22 名临床诊断为 PD 的患者和 33 名健康个体的头发样本中钙、铁和锌的浓度,这些患者代表了巴西健康登记处可获得的所有患者的整个队列。虽然在 PD 组中未发现 Ca 和 Fe 改变与精神科投诉有关,但在 PD 患者中,与抑郁和一些精神病症状相关的 Zn 水平明显更高。在 SCOPA-PC 的个体域中,与对照组和未出现这些症状的 PD 患者相比,Zn 水平的升高与幻觉、错觉和妄想观念的存在显著相关。尽管我们的样本量较小,并且需要在更大和更异质的人群中复制结果,但我们的结果为监测 Zn 水平作为精神科投诉的潜在生物标志物提供了新的视角,并且可能有助于开发更有效的治疗方法来管理 PD 患者伴发的精神障碍。